MesoStem
Using its universal human embryonic stem cell (ESC) line, PluraStem, Escape is creating an
off-the-shelf MSC that can be transplanted into patients of any HLA type without the need for lifelong
immunosuppression. Escape's MSC product, MesoStem, holds the key advantage of stable, long-term
suppression of the autoimmune destruction process responsible for type I diabetes progression.
Other advantages over unmodified MSC products include more favorable dosing schedules and predictable
clinical efficacy. A partial list of the disease indications potentially treatable with Escape's
MesoStem product is shown below:
Clinical Indications for MesoStem |
Type I diabetes (onset/progression) |
Psoriasis |
Systemic Lupus Erythematosus |
Inflammatory Bowel Disease |
Rheumatoid Arthritis |
Graft-Versus-Host Disease |